Discovery of NR2B-selective antagonists via scaffold hopping and pharmacokinetic profile optimization
作者:Kosuke Anan、Moriyasu Masui、Aya Tazawa、Minoru Tomida、Yoshihiro Haga、Masaharu Kume、Shoichi Yamamoto、Shunji Shinohara、Hiroki Tsuji、Shinji Shimada、Shigenori Yagi、Nobuyoshi Hasebe、Hiroyuki Kai
DOI:10.1016/j.bmcl.2019.02.017
日期:2019.5
Selective N-methyl-d-aspartate receptor subunit 2B (NR2B) antagonists show potential as analgesic drugs, and do not cause side effects associated with non-selective N-methyl-d-aspartate (NMDA) antagonists. Using a scaffold-hopping approach, we previously identified isoxazole derivative 4 as a potent selective NR2B antagonist. In this study, further scaffold hopping of isoxazole derivative 4 and optimization
选择性N-甲基-d-天冬氨酸受体亚基2B(NR2B)拮抗剂具有作为止痛药的潜力,并且不会引起与非选择性N-甲基-d-天冬氨酸(NMDA)拮抗剂相关的副作用。使用脚手架跳方法,我们以前确定异恶唑衍生物4作为有效的选择性NR2B拮抗剂。在这项研究中,异恶唑衍生物4的进一步跳跃和对其药代动力学特性的优化导致发现了口服生物利用性化合物6v。在一项大鼠镇痛研究中,6v表现出对神经性疼痛的镇痛作用。